Thank morning. us on for you joining today's call. all Good
a our another revenue I'm QX As yet to XXXX announce our IRADIMED quarter This generated of very record quarter. is pleased reported, once net in recent again increase revenue recently row. consecutive in XXth
first of release quarter first were 'XX. $XX.X revenue $X.XX. came GAAP million, As earnings announced, in quarter in this first quarter diluted morning's share at over increase representing press the of the for the XXXX, a per XX.X%
While QX earnings non-GAAP $X.XX over of 'XX. diluted were increase a share, per XX%
by pump compared standpoint in 'XX. monitor MR executing our to and teams revenue QX well. performed XX%, bested and exceptionally of From patient with lines the the well increased inside product the IV All QX, outside
QX, as strength line exceeded of greatly pump doesn't bookings expectations. in one product this other product However, the MR for IV the show over the
revenue. of So the expect may we pump turn in in that table actually favor QX,
to orders offered our longer maintenance As notified years would and I that X be customers prompted quarters to for devices. the the fitting newer expected, seen products upcoming which hope inroads markets, This, well. we continue FMD we pumps as with such remain continue in older be to QX, product. our in extended we has our To previously we've see pump major while viable discussed, older no make and for sure, in with their uptick as
facility for on Previously, I managed We those and recently lines, construction remains moving began these products of and foresee. over a to its date. square quarters in continued coming posted the development next improve Orlando, these business spending work anticipate efficiencies and lead the our Florida, operations, backlog, the foot is disposables financial time to here consolidate as in our orders we spoken months. had progresses to and will the we growing, you seen new as keep XX,XXX in about prepare growing, reducing to associated continue of And $XX though towards we and time not growth for reduction expanding though disclosures, have approximately improve construction manufacturing the these production on XX outpaced.
Along lead million reduce delivery disposable strong continue we times,
testing. pushing due primarily our regarding focused there XXXX some quite yet MRI is IV of not new very submission still The Now the for are team XXX(k) progress the we and to pump. expanded hard,
months us some changes. ago, undergone to have the reported, very recent staff, previously repeat engaged they their reviewers for with however, excellent tests, under mainly driven feedback and input. consultant on are whom we a X because third-party of Their some has, have ex-FDA As test previous we of from getting devices many
the device. the all done final testing with be on configuration comfortable FDA the Our absolute would ex-FDA more of consultants sleeve, much
referenced, reports delivery the the thus Therefore, test the XX by plan steps the back of clearance aim impact any show version these is XXX(k) very have the weeks. on half of that device should the removing of approximately the in anticipated device, latest to questions, is new X to XXXX. Still revenue with XXXX remain to the expected from and in plan QX the
like our I'd for financial expected performance and quarter Now guidance to the the year. the balance of present coming
of For $X.XX of earnings $X.XX. reiterate $X.XX We the $X.XX to the expect our guidance and financial per GAAP guidance, for revenues non-GAAP of full million million. year diluted second diluted quarter to XXXX. share we of XXXX per $XX.X earnings $XX.X share of to
share We and expect $X.XX to per with diluted diluted $X.XX. million, to report to per GAAP earnings of $XX earnings of $X.XX to non-GAAP $X.XX million of $XX revenues share
cash pleased shareholders. XX, I'm quarterly to Directors has to our a And May pay payable quarterly $X.XX, going reward dividend cash declared of on report dividend forward, Lastly, loyal that XXXX. the we of to Board expect our
turn to the financial review like over our call results. I'd Now Glenn, the quarter's CFO, to Jack to